MCK vs. COR, CAH, ZTS, BDX, GILD, HCA, GSK, BMY, EW, and DXCM
Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Zoetis (ZTS), Becton, Dickinson and Company (BDX), Gilead Sciences (GILD), HCA Healthcare (HCA), GSK (GSK), Bristol-Myers Squibb (BMY), Edwards Lifesciences (EW), and DexCom (DXCM). These companies are all part of the "medical" sector.
Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.
Cencora has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.
97.5% of Cencora shares are held by institutional investors. Comparatively, 85.1% of McKesson shares are held by institutional investors. 15.8% of Cencora shares are held by insiders. Comparatively, 0.2% of McKesson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
McKesson received 208 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.09% of users gave McKesson an outperform vote while only 65.12% of users gave Cencora an outperform vote.
Cencora currently has a consensus target price of $233.90, indicating a potential upside of 4.44%. McKesson has a consensus target price of $536.71, indicating a potential upside of 1.49%. Given McKesson's higher possible upside, research analysts clearly believe Cencora is more favorable than McKesson.
In the previous week, Cencora had 8 more articles in the media than McKesson. MarketBeat recorded 32 mentions for Cencora and 24 mentions for McKesson. Cencora's average media sentiment score of 0.38 beat McKesson's score of 0.34 indicating that McKesson is being referred to more favorably in the news media.
McKesson has a net margin of 0.99% compared to McKesson's net margin of 0.67%. McKesson's return on equity of 268.67% beat Cencora's return on equity.
Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.5%. Cencora pays out 22.3% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has increased its dividend for 1 consecutive years and McKesson has increased its dividend for 16 consecutive years.
Summary
McKesson beats Cencora on 13 of the 21 factors compared between the two stocks.
Get McKesson News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
McKesson Competitors List
Related Companies and Tools
